Cytokinetics, Amgen increase scope of heart failure deal

Amgen and Cytokinetics agreed to expand an existing licensing deal centered on the experimental heart failure drug omecamtiv mecarbil and related compounds to include the Japanese market. The expanded deal entitles Cytokinetics to $25 million in upfront payment and as much as $50 million in milestone fees plus sales royalties.

View Full Article in:

Los Angeles Business Journal (free registration) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI